BACKGROUND: The Genitourinary Radiation Oncologists of Canada (GUROC) published a three-group risk stratification (RS) system to assist prostate cancer decision-making in 2001. The objective of this project is to use the ProCaRS database to statistically model the predictive accuracy and clinical utility of a proposed new multi-group RS schema. METHODS: The RS analyses utilized the ProCaRS database that consists of 7974 patients from four Canadian institutions. Recursive partitioning analysis (RPA) was utilized to explore the sub-stratification of groups defined by the existing three-group GUROC scheme. 10-fold cross-validated C-indices and the Net Reclassification Index were both used to assess multivariable models and compare the predictive accuracy of existing and proposed RS systems, respectively. RESULTS: The recursive partitioning analysis has suggested that the existing GUROC classification system could be altered to accommodate as many as six separate and statistical unique groups based on differences in BFFS (C-index 0.67 and AUC 0.70). GUROC low-risk patients would be divided into new favorable-low and low-risk groups based on PSA ⩽6 and PSA >6. GUROC intermediate-risk patients can be subclassified into low-intermediate and high-intermediate groups. GUROC high-intermediate-risk is defined as existing GUROC intermediate-risk with PSA >=10 AND either T2b/c disease or T1T2a disease with Gleason 7. GUROC high-risk patients would be subclassified into an additional extreme-risk group (GUROC high-risk AND (positive cores ⩾87.5% OR PSA >30). CONCLUSIONS: Proposed RS subcategories have been identified by a RPA of the ProCaRS database.
BACKGROUND: The Genitourinary Radiation Oncologists of Canada (GUROC) published a three-group risk stratification (RS) system to assist prostate cancer decision-making in 2001. The objective of this project is to use the ProCaRS database to statistically model the predictive accuracy and clinical utility of a proposed new multi-group RS schema. METHODS: The RS analyses utilized the ProCaRS database that consists of 7974 patients from four Canadian institutions. Recursive partitioning analysis (RPA) was utilized to explore the sub-stratification of groups defined by the existing three-group GUROC scheme. 10-fold cross-validated C-indices and the Net Reclassification Index were both used to assess multivariable models and compare the predictive accuracy of existing and proposed RS systems, respectively. RESULTS: The recursive partitioning analysis has suggested that the existing GUROC classification system could be altered to accommodate as many as six separate and statistical unique groups based on differences in BFFS (C-index 0.67 and AUC 0.70). GUROC low-risk patients would be divided into new favorable-low and low-risk groups based on PSA ⩽6 and PSA >6. GUROC intermediate-risk patients can be subclassified into low-intermediate and high-intermediate groups. GUROC high-intermediate-risk is defined as existing GUROC intermediate-risk with PSA >=10 AND either T2b/c disease or T1T2a disease with Gleason 7. GUROC high-risk patients would be subclassified into an additional extreme-risk group (GUROC high-risk AND (positive cores ⩾87.5% OR PSA >30). CONCLUSIONS: Proposed RS subcategories have been identified by a RPA of the ProCaRS database.
Authors: Thomas M Pisansky; Daniel Hunt; Leonard G Gomella; Mahul B Amin; Alexander G Balogh; Daniel M Chinn; Michael J Seider; Marie Duclos; Seth A Rosenthal; Glenn S Bauman; Elizabeth M Gore; Marvin Z Rotman; Himanshu R Lukka; William U Shipley; James J Dignam; Howard M Sandler Journal: J Clin Oncol Date: 2014-12-22 Impact factor: 44.544
Authors: David Guy; Rachel Glicksman; Roger Buckley; Patrick Cheung; Hans Chung; Stanley Flax; David Hajek; Andrew Loblaw; Gerard Morton; Jeffery Noakes; Les Spevack; Joseph L K Chin; George Rodrigues Journal: Can Urol Assoc J Date: 2022-04 Impact factor: 2.052
Authors: David Tiberi; George Rodrigues; Tom Pickles; Jim Morris; Juanita Crook; Andre-Guy Martin; Fabio Cury; Charles Catton; Himu Lukka; Andrew Warner; Daniel Taussky Journal: Can Urol Assoc J Date: 2017 Mar-Apr Impact factor: 1.862
Authors: S Roy; M E Hyndman; B Danielson; A Fairey; R Lee-Ying; W Y Cheung; A R Afzal; Y Xu; T Abedin; H C Quon Journal: Curr Oncol Date: 2019-08-01 Impact factor: 3.677
Authors: David Guy; Gabriella Ghanem; Andrew Loblaw; Roger Buckley; Beverly Persaud; Patrick Cheung; Hans Chung; Cyril Danjoux; Gerard Morton; Jeff Noakes; Les Spevack; David Hajek; Stanley Flax Journal: Can Urol Assoc J Date: 2016 Mar-Apr Impact factor: 1.862
Authors: Andrew Warner; Tom Pickles; Juanita Crook; Andre-Guy Martin; Luis Souhami; Charles Catton; Himu Lukka; George Rodrigues Journal: Cureus Date: 2015-06-11
Authors: Vincent J Gnanapragasam; Artitaya Lophatananon; Karen A Wright; Kenneth R Muir; Anna Gavin; David C Greenberg Journal: PLoS Med Date: 2016-08-02 Impact factor: 11.069
Authors: Yvonka van Wijk; Bram Ramaekers; Ben G L Vanneste; Iva Halilaj; Cary Oberije; Avishek Chatterjee; Tom Marcelissen; Arthur Jochems; Henry C Woodruff; Philippe Lambin Journal: Cancers (Basel) Date: 2021-05-29 Impact factor: 6.639